journal article·2025-07-25Open access

Nickel Ferrite Nanoparticles for In Vivo Multimodal Magnetic Resonance and Magnetic Particle Imaging

Vít Herynek, Lenka Rajsiglová, Michal Babič, Monika Švábová, Jaroslav Kohout, Miroslav Veverka, Tomáš Kmječ, Lenka Kubíčková, Jiří Karela, Filip Gregar, Martin Loula, Stanislava Matějková, Luděk Šefc, Luca Vannucci

ACS Applied Nano Materials· Volume 8· Issue 29

Abstract

High Resolution Image Download MS PowerPoint Slide Magnetic nanoparticles have been at the center of biomedical research for decades, primarily for their applications in magnetic resonance imaging (MRI) and magnetic particle imaging (MPI). Superparamagnetic particles, typically based on iron oxide crystals, are effective in both modalities, although each requires distinct magnetic properties for optimal performance. We investigated the performance of nanoparticles based on a nickel-substituted ferrite core and compared them to standard maghemite iron oxide nanoparticles. We synthesized γ-Fe 2 O 3 and Ni x Fe 2– x O 3 nanoparticles and coated them with a statistical copolymer poly( N, N -dimethylacrylamide- co -acrylic acid). In vitro testing included X-ray diffraction (XRD), Mössbauer spectroscopy, magnetometry, magnetic resonance relaxometry, magnetic particle spectroscopy, and imaging. In vivo testing involved monitoring of nanoparticle biodistribution using MPI and MRI after intracardial application in a murine model. Mössbauer spectra suggest that the Ni-substituted nanoparticles consist of a stoichiometric NiFe 2 O 4 ferrite and a poorly crystalline antiferromagnetic iron(III) oxide-hydroxide phase. Amorphous-like impurities in Ni x Fe 2– x O 3 nanoparticles were probably responsible for lower saturation magnetization than that of γ-Fe 2 O 3 nanoparticles, as was proved by magnetometry, which led to lower r 2 relaxivity. However, MPI revealed a higher signal in the spectrum and superior imaging performance of Ni x Fe 2– x O 3 compared to γ-Fe 2 O 3 particles, likely due to shorter Néél and Brownian relaxation times. Both types of nanoparticles showed similar performance in bimodal MRI/MPI imaging in vivo. They were detected in the liver immediately after application and appeared in the spleen within 24 h. Long-term localization in the lymph nodes was also observed. Substituting an iron with a nickel ion in the core altered the magnetic properties, leading to lower saturation magnetization and an increased signal in the magnetic particle spectra, which enhanced their performance in MPI. This study demonstrates that γ-Fe 2 O 3 and Ni x Fe 2– x O 3 nanoparticles are both suitable for combined MRI/MPI imaging; magnetic particle imaging provides a highly specific signal for anatomical magnetic resonance images.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Characterization and Applications of Magnetic Nanoparticles · Nanoparticle-Based Drug Delivery · Magnetic Properties and Synthesis of Ferrites

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Center for Advanced Preclinical Imaging (CAPI), First Faculty of Medicine

Charles University

Laboratory of Immunotherapy, Institute of Microbiology

Czech Academy of Sciences

Polymer and Colloid Immunotherapeutics

Institute of Macromolecular Chemistry, Czech Academy of Sciences

Department of Low Temperature Physics, Faculty of Mathematics and Physics

Department of Magnetics and Superconductors

Institute of Physics, Czech Academy of Sciences

Department of Analytical Chemistry, Faculty of Science

Palacký University Olomouc

Analytical Laboratory, Institute of Organic Chemistry and Biochemistry

Funding

European Regional Development Fund · Ministerstvo ?kolstv?, Ml?de?e a Telov?chovy · Grantov? Agentura Cesk? Republiky · Akademie Ved Cesk? Republiky · Univerzita Palack?ho v Olomouci · NextGenerationEU

References (64)

Show source-provided references
1. 10.3390/pharmaceutics1307094310.3390/pharmaceutics13070943 ↗
2. 10.1148/radiol.201716275910.1148/radiol.2017162759 ↗
3. 10.3978/j.issn.2223-4292.2011.08.0310.3978/j.issn.2223-4292.2011.08.03 ↗
4. 10.3748/wjg.v21.i47.1340010.3748/wjg.v21.i47.13400 ↗
5. 10.1039/D1NR05670K10.1039/D1NR05670K ↗
6. 10.3390/ma1311258610.3390/ma13112586 ↗
7. 10.1038/nature0380810.1038/nature03808 ↗
8. 10.1109/TMI.2012.221797910.1109/TMI.2012.2217979 ↗
9. 10.1118/1.483721610.1118/1.4837216 ↗
10. 10.1016/j.jmmm.2008.05.02810.1016/j.jmmm.2008.05.028 ↗
11. 10.1016/j.jallcom.2018.01.02310.1016/j.jallcom.2018.01.023 ↗
12. 10.1016/j.apsusc.2014.08.19310.1016/j.apsusc.2014.08.193 ↗
13. 10.1039/C5RA07484C10.1039/C5RA07484C ↗
14. 10.1002/pssb.20030454910.1002/pssb.200304549 ↗
15. 10.1063/1.490761010.1063/1.4907610 ↗
16. 10.1002/smll.20240294010.1002/smll.202402940 ↗
17. 10.3390/app11231130110.3390/app112311301 ↗
18. 10.1016/j.jmmm.2016.11.03310.1016/j.jmmm.2016.11.033 ↗
19. 10.1007/s11051-021-05164-x10.1007/s11051-021-05164-x ↗
20. 10.1016/j.mset.2019.01.00910.1016/j.mset.2019.01.009 ↗
21. 10.1007/s10948-011-1259-510.1007/s10948-011-1259-5 ↗
22. 10.1016/j.ceramint.2020.03.28710.1016/j.ceramint.2020.03.287 ↗
23. 10.3390/nano1303045210.3390/nano13030452 ↗
24. 10.4103/jmss.JMSS_59_1810.4103/jmss.JMSS_59_18 ↗
25. 10.7508/jns.2015.02.00110.7508/jns.2015.02.001 ↗
26. 10.1016/j.matchemphys.2020.12417810.1016/j.matchemphys.2020.124178 ↗
27. 10.1016/j.jallcom.2023.17302210.1016/j.jallcom.2023.173022 ↗
28. 10.1016/j.jallcom.2023.17340710.1016/j.jallcom.2023.173407 ↗
29. 10.1016/j.colsurfa.2023.13203710.1016/j.colsurfa.2023.132037 ↗
30. 10.1080/1547691X.2024.241698810.1080/1547691X.2024.2416988 ↗
31. 10.1021/bc800373x10.1021/bc800373x ↗
32. 10.1038/nmeth.208910.1038/nmeth.2089 ↗
33. 10.1016/j.jmmm.2010.02.04010.1016/j.jmmm.2010.02.040 ↗
34. 10.1021/acsnano.1c1059410.1021/acsnano.1c10594 ↗
35. 10.1002/sia.228510.1002/sia.2285 ↗
36. 10.1007/s10751-012-0732-210.1007/s10751-012-0732-2 ↗
37. Rodríguez-Carvajal J. · Newsletter · 2001 · 26 · 12
38. 10.18416/IJMPI.2023.230307910.18416/IJMPI.2023.2303079 ↗
39. 10.1002/jbm.b.3413710.1002/jbm.b.34137 ↗
40. 10.1016/j.jmmm.2006.03.06910.1016/j.jmmm.2006.03.069 ↗
41. 10.1021/bc700410z10.1021/bc700410z ↗
42. 10.1021/bc060186c10.1021/bc060186c ↗
43. 10.1023/A:101109271213610.1023/A:1011092712136 ↗
44. 10.1016/j.jmmm.2018.12.03710.1016/j.jmmm.2018.12.037 ↗
45. 10.1016/j.jmmm.2018.11.12610.1016/j.jmmm.2018.11.126 ↗
46. 10.1039/C6CE02421A10.1039/C6CE02421A ↗
47. 10.1016/j.jmmm.2019.16608310.1016/j.jmmm.2019.166083 ↗
48. 10.1180/claymin.1992.027.1.0610.1180/claymin.1992.027.1.06 ↗
49. 10.1088/0953-8984/16/24/01710.1088/0953-8984/16/24/017 ↗
50. 10.1186/1752-153X-6-2310.1186/1752-153X-6-23 ↗
51. 10.1016/S0921-5107(04)00427-110.1016/S0921-5107(04)00427-1 ↗
52. 10.1002/ppsc.20220010610.1002/ppsc.202200106 ↗
53. 10.1007/s41779-022-00784-510.1007/s41779-022-00784-5 ↗
54. 10.1016/j.materresbull.2011.09.00910.1016/j.materresbull.2011.09.009 ↗
55. 10.1148/rg.26606501410.1148/rg.266065014 ↗
56. 10.2214/ajr.155.5.212096310.2214/ajr.155.5.2120963 ↗
57. 10.3390/pharmaceutics1507198210.3390/pharmaceutics15071982 ↗
58. 10.4103/0976-0105.17770310.4103/0976-0105.177703 ↗
59. 10.1088/0031-9155/61/12/458310.1088/0031-9155/61/12/4583 ↗
60. 10.1007/978-3-642-24133-8_4010.1007/978-3-642-24133-8_40 ↗
61. 10.18416/IJMPI.2022.220304210.18416/IJMPI.2022.2203042 ↗
62. 10.1038/s41598-021-00845-y10.1038/s41598-021-00845-y ↗
63. 10.1016/j.eurpolymj.2014.07.02210.1016/j.eurpolymj.2014.07.022 ↗
64. 10.1080/17435889.2024.234504410.1080/17435889.2024.2345044 ↗